clinical trial · NCT03165240
This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated
Boehringer Ingelheim·phase1·completed·n = 62
Diabetic NephropathiesBI 690517EplerenonePlacebo
brief summary
The primary objective of this current trial is to investigate the safety and tolerability of 3 oral doses of BI 690517 over 28 days in female and male patients with diabetic nephropathy as add-on-therapy to Angiotensin Converting Enzyme inhibitor \[ACEi\] or Angiotensin-receptor blockers \[ARB\]. Secondary objective is to evaluate the change from baseline in Urine Albumin-to-Creatinine Ratio \[UACR\].
started
Oct 5, 2017
primary completion
Apr 16, 2020
completion
May 7, 2020
last updated
Sep 20, 2024
official title
Randomised, Double-blind, Placebo-controlled (Within Dose Groups) and Active Controlled (Eplerenone Group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients With Diabetic Nephropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol